Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPY2R | P49146 | 6/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MTTP | P55157 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4339051 | 0.78 | MAOB (0.47) | RAB9ALMNAKDM4E | |
| SCHEMBL4339056 | 0.78 | MAOB (0.47) | RAB9ALMNAKDM4E | |
| SCHEMBL2869968 | 0.78 | CRACR2A (0.49) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL240711 | 0.77 | ALDH1A1 (0.64) | MAPTLMNADHFR | |
| SCHEMBL8272499 | 0.76 | NPY2R (0.47) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL3425880 | 0.75 | ALDH1A1 (0.46) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL27660601 | 0.74 | MAPT (0.41) | MAPTMEN1KMT2AIDO1NPC1 | |
| SCHEMBL3426220 | 0.71 | MAPT (0.43) | MAPTMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL4329124 | 0.70 | MAOB (0.44) | MAPTMEN1KMT2AL3MBTL1KDM4E | |
| SCHEMBL4322348 | 0.70 | MAOB (0.44) | MAPTMEN1KMT2AL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718671-B2 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | claimed |
| CN-1849301-A | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS INC (US) | 2006-10-18 | — | — | CN | claimed |
| EP-1648862-A2 | SUBSTITUTED ARYLTHIOUREA DERIVATIVES USEFUL AS INHIBITORS OF VIRAL REPLICATION | Achillion Pharmaceuticals, Inc. (US) | 2006-04-26 | — | — | EP | claimed |
| US-20050032849-A1 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | claimed |
| WO-2005007601-A2 | SUBSTITUTED ARYLTHIOUREA DERIVATIVES USEFUL AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | claimed |
| US-7718671-B2 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718671-B2 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718671-B2 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20050032849-A1 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032849-A1 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | TPMT, NAT1, GOT1 | MAPT 1972/4885MEN1 4515/4885KMT2A 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.